Parkinsonism due to ephedrone neurotoxicity: a case report.
Colosimo
C
C
Guidi
M
M
D000328:Adult; D000978:Antiparkinson Agents / Q000627:therapeutic use; D003342:Corpus Striatum / Q000000981:diagnostic imaging* / Q000187:drug effects* / Q000473:pathology; D005061:Europe, Eastern / Q000453:epidemiology; D020233:Gait Disorders, Neurologic / Q000139:chemically induced / Q000503:physiopathology; D006801:Humans; D013287:Illicit Drugs / Q000138:chemical synthesis / Q000506:poisoning; D008279:Magnetic Resonance Imaging; D008297:Male; D020149:Manganese Poisoning / Q000000981:diagnostic imaging* / Q000473:pathology / Q000503:physiopathology; D009434:Neural Pathways / Q000000981:diagnostic imaging / Q000187:drug effects / Q000473:pathology; D009483:Neuropsychological Tests; D010302:Parkinson Disease, Secondary / Q000139:chemically induced* / Q000000981:diagnostic imaging* / Q000473:pathology; D017729:Presynaptic Terminals / Q000187:drug effects / Q000473:pathology / Q000528:radiation effects; D011427:Propiophenones / Q000138:chemical synthesis / Q000506:poisoning*; D013378:Substantia Nigra / Q000000981:diagnostic imaging / Q000187:drug effects / Q000473:pathology; D015899:Tomography, Emission-Computed, Single-Photon; D017211:Treatment Failure
D000978:Antiparkinson Agents; D013287:Illicit Drugs; D011427:Propiophenones; C047806:monomethylpropion